FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076644112> ?p ?o ?g. }

• W2076644112 endingPage "e2" @default.
• W2076644112 startingPage "e2.89" @default.
• W2076644112 abstract "<h3>Introduction</h3> The natalizumab (TYSABRI^®) Observational Program (TOP) is an ongoing, open–label, 10–year prospective study of relapsing–remitting Multiple Sclerosis (RRMS) patients in European, Australian, and Canadian clinical settings. Patients must be naïve to natalizumab when deciding to enrol but may have received other disease–modifying therapies (DMTs) pre–natalizumab. The objective of this analysis was to evaluate interim efficacy and safety data in the subset of patients in the United Kingdom (UK). <h3>Methods</h3> Baseline characteristics were summarised. Annualised relapse rate (ARR) was analysed for overall pre–and postbaseline differences as well as by treatment and relapse histories at baseline. Expanded Disability Status Scale (EDSS) scores were evaluated at baseline and years 1 and 2. The incidence of serious adverse events (SAEs) was evaluated. <h3>Results</h3> As of June 1, 2012, 117 patients were enroled in the UK. Most (80.3%) were female; mean age was 39.1 years. The median duration of RRMS was 5.6 (range 0.4–25.3) years. The median number of relapses in the year prior to natalizumab treatment was 2.0 (range 1.0–6.0); 24.8% of patients had 1 relapse and 75.2% had >1 relapse in the prior year. At baseline, 35.0% of patients were treatment naïve, 49.6% were treated with 1 DMT, and 15.4% were treated with >1 DMT prior to natalizumab. Approximately half (51.3%) had a history of interferon use, 25.6% had a history of glatiramer acetate use, and 1.7% had a history of immunosuppressant use. Most patients (60.7%, n=71) have been followed for at least 12 months; 39.3% (n=46) have been followed for at least 18 months. Patients received a median of 15 (range 1–27) natalizumab infusions. ARR overall decreased from 2.26 at baseline to 0.38 on treatment (n=117; P<0.0001). ARR decreased significantly from baseline regardless of baseline treatment history (treatment naïve [n=41]: 2.54 at baseline vs 0.48 on treatment, P<0.0001; 1 prior DMT [n=58]: 2.14 at baseline vs 0.36 on treatment, P<0.0001; >1 prior DMT [n=18]: 2.00 at baseline vs 0.26 on treatment, P=0.0003) or relapse history (1 relapse in prior year [n=29]: 1.00 at baseline vs 0.27 on treatment, P<0.0001); >1 relapse [n=88]: 2.67 at baseline vs 0.43 on treatment, P<0.0001). EDSS scores were stable with a mean of 4.2 at baseline (n=115), 4.0 at month 6 (n=33), 4.4 at year 1 (n=19), and 4.3 at year 2 (n=9). No cases of progressive multifocal leukoencephalopathy, malignancy, or opportunistic infections were reported. <h3>Conclusions</h3> In this interim analysis of UK TOP results, patients treated with natalizumab had significantly improved ARRs, regardless of baseline treatment or relapse history. EDSS scores remained stable over time. Safety data were consistent with natalizumab9s known safety profile. Analyses of UK TOP data over longer periods of time will further characterise the effect of natalizumab on disability, as well as on other long–term efficacy and safety parameters in a real–world setting." @default.
• W2076644112 created "2016-06-24" @default.
• W2076644112 creator A5048071526 @default.
• W2076644112 creator A5085594360 @default.
• W2076644112 creator A5087532051 @default.
• W2076644112 date "2013-10-09" @default.
• W2076644112 modified "2023-09-26" @default.
• W2076644112 title "EFFICACY AND SAFETY OF NATALIZUMAB TREATMENT FOR RELAPSING–REMITTING MULTIPLE SCLEROSIS: INTERIM RESULTS OF THE TYSABRI®OBSERVATIONAL PROGRAMME IN THE UK" @default.
• W2076644112 doi "https://doi.org/10.1136/jnnp-2013-306573.179" @default.
• W2076644112 hasPublicationYear "2013" @default.
• W2076644112 type Work @default.
• W2076644112 sameAs 2076644112 @default.
• W2076644112 citedByCount "4" @default.
• W2076644112 countsByYear W20766441122014 @default.
• W2076644112 countsByYear W20766441122016 @default.
• W2076644112 crossrefType "journal-article" @default.
• W2076644112 hasAuthorship W2076644112A5048071526 @default.
• W2076644112 hasAuthorship W2076644112A5085594360 @default.
• W2076644112 hasAuthorship W2076644112A5087532051 @default.
• W2076644112 hasConcept C118552586 @default.
• W2076644112 hasConcept C120665830 @default.
• W2076644112 hasConcept C121332964 @default.
• W2076644112 hasConcept C126322002 @default.
• W2076644112 hasConcept C1862650 @default.
• W2076644112 hasConcept C197934379 @default.
• W2076644112 hasConcept C207103383 @default.
• W2076644112 hasConcept C23131810 @default.
• W2076644112 hasConcept C2778577042 @default.
• W2076644112 hasConcept C2780640218 @default.
• W2076644112 hasConcept C2780892749 @default.
• W2076644112 hasConcept C2781004633 @default.
• W2076644112 hasConcept C3020694758 @default.
• W2076644112 hasConcept C44249647 @default.
• W2076644112 hasConcept C535046627 @default.
• W2076644112 hasConcept C61511704 @default.
• W2076644112 hasConcept C61943457 @default.
• W2076644112 hasConcept C71924100 @default.
• W2076644112 hasConceptScore W2076644112C118552586 @default.
• W2076644112 hasConceptScore W2076644112C120665830 @default.
• W2076644112 hasConceptScore W2076644112C121332964 @default.
• W2076644112 hasConceptScore W2076644112C126322002 @default.
• W2076644112 hasConceptScore W2076644112C1862650 @default.
• W2076644112 hasConceptScore W2076644112C197934379 @default.
• W2076644112 hasConceptScore W2076644112C207103383 @default.
• W2076644112 hasConceptScore W2076644112C23131810 @default.
• W2076644112 hasConceptScore W2076644112C2778577042 @default.
• W2076644112 hasConceptScore W2076644112C2780640218 @default.
• W2076644112 hasConceptScore W2076644112C2780892749 @default.
• W2076644112 hasConceptScore W2076644112C2781004633 @default.
• W2076644112 hasConceptScore W2076644112C3020694758 @default.
• W2076644112 hasConceptScore W2076644112C44249647 @default.
• W2076644112 hasConceptScore W2076644112C535046627 @default.
• W2076644112 hasConceptScore W2076644112C61511704 @default.
• W2076644112 hasConceptScore W2076644112C61943457 @default.
• W2076644112 hasConceptScore W2076644112C71924100 @default.
• W2076644112 hasIssue "11" @default.
• W2076644112 hasLocation W20766441121 @default.
• W2076644112 hasOpenAccess W2076644112 @default.
• W2076644112 hasPrimaryLocation W20766441121 @default.
• W2076644112 hasRelatedWork W1983662063 @default.
• W2076644112 hasRelatedWork W2001155665 @default.
• W2076644112 hasRelatedWork W2068638773 @default.
• W2076644112 hasRelatedWork W2076644112 @default.
• W2076644112 hasRelatedWork W2146675512 @default.
• W2076644112 hasRelatedWork W2405536231 @default.
• W2076644112 hasRelatedWork W2571212086 @default.
• W2076644112 hasRelatedWork W2801606837 @default.
• W2076644112 hasRelatedWork W3188458931 @default.
• W2076644112 hasRelatedWork W4214913356 @default.
• W2076644112 hasVolume "84" @default.
• W2076644112 isParatext "false" @default.
• W2076644112 isRetracted "false" @default.
• W2076644112 magId "2076644112" @default.
• W2076644112 workType "article" @default.